首页> 美国卫生研究院文献>Oncotarget >Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: a meta-analysis
【2h】

Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: a meta-analysis

机译:SIRT1在非小细胞肺癌中表达的预后和临床病理学意义:一项荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The prognosis of NSCLC is extremely poor and it is urgently to find a new marker. Numerous studies have confirmed that silent mating type information regulation 2 homolog-1 (sirtuin1; SIRT1) is abnormally expressed in NSCLC. This meta-analysis was performed to investigate the prognostic and clinicopathological significance of SIRT1 in NSCLC. A total of seven eligible studies, including 6 on clinicopathological features, 7 on prognosis were identified from the databases. Pooled hazard ratios (HRs) or odds ratios (OR) and 95% confidence intervals (95% CIs) were calculated using random- or fixed-effects models. Results revealed that high expression of SIRT1 was associated with poor overall survival in NSCLC patients (HR=1.99, 95% CI: 1.33-2.98, P=0.0009). Moreover, SIRT1 were related to histological grade (OR= 2.00, 95% CI= 1.05–3.78, P= 0.02) of NSCLC patients. In conclusion, our present meta-analysis indicated that SIRT1 may serve as a promising marker for prognosis of patients with NSCLC.
机译:非小细胞肺癌(NSCLC)是最常见的肺癌类型。 NSCLC的预后极差,迫切需要寻找新的标志物。大量研究已经证实,沉默交配型信息调节基因2 homolog-1(sirtuin1; SIRT1)在NSCLC中异常表达。进行这项荟萃分析,以调查SIRT1在NSCLC中的预后和临床病理意义。从数据库中鉴定出总共7项合格研究,包括6项临床病理特征,7项预后。使用随机或固定效应模型计算汇总风险比(HRs)或优势比(OR)和95%置信区间(95%CI)。结果显示,SIRT1的高表达与NSCLC患者的总生存期差有关(HR = 1.99,95%CI:1.33-2.98,P = 0.0009)。此外,SIRT1与NSCLC患者的组织学分级(OR = 2.00,95%CI = 1.05-3.78,P = 0.02)相关。总之,我们目前的荟萃分析表明SIRT1可以作为NSCLC患者预后的有前途的标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号